Randomized Trial of SGLT2i in Heart Transplant Recipients

NCT06625073 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

200

Enrollment

FED

Sponsor class

Conditions

Heart Transplant
Cardiovascular Disease
Kidney Disease

Interventions

DRUG: Empagliflozin
DRUG: Placebo

Sponsor

VA Office of Research and Development